Matsushita Yuto, Iwashita Yuji, Ohtsuka Shunsuke, Ohnishi Ippei, Yamashita Takashi, Miyake Hideaki, Sugimura Haruhiko
Department of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Genes Environ. 2021 Dec 2;43(1):52. doi: 10.1186/s41021-021-00228-9.
DNA adducts, covalent modifications to DNA due to exposure to specific carcinogens, cause the mispairing of DNA bases, which ultimately results in DNA mutations. DNA methylation in the promoter region, another type of DNA base modification, alters the DNA transcription process, and has been implicated in carcinogenesis in humans due to the down-regulation of tumor suppressor genes. Difficulties are associated with demonstrating the existence of DNA adducts or chemically modified bases in the human urological system. Apart from aristolochic acid-DNA adducts, which cause urothelial carcinoma and endemic nephropathy in a particular geographical area (Balkan), limited information is currently available on DNA adduct profiles in renal cell carcinoma and upper urinary tract urothelial carcinoma, including renal pelvic cancer and ureteral cancer.
To elucidate the significance of DNA adducts in carcinogenesis in the urothelial system, we investigated 53 DNA adducts in the non-tumoral renal parenchyma and non-tumoral renal pelvis of patients with renal cell carcinoma, upper urinary tract urothelial carcinoma, and other diseases using liquid chromatography coupled with tandem mass spectrometry. A comparative analysis of tissue types, the status of malignancy, and clinical characteristics, including lifestyle factors, was performed.
C5-Methyl-2'-deoxycytidine, C5-hydroxymethyl-2'-deoxycytidine (5hmdC), C5-formyl-2'-deoxycytidine, 2'-deoxyinosine, C8-oxo-2'-deoxyadenosine, and C8-oxo-2'-deoxyguanosine (8-OHdG) were detected in the renal parenchyma and renal pelvis. 8-OHdG was more frequently detected in the renal pelvis than in the renal cortex and medulla (p = 0.048 and p = 0.038, respectively). 5hmdC levels were significantly lower in the renal pelvis of urothelial carcinoma patients (n = 10) than in the urothelium of patients without urothelial carcinoma (n = 15) (p = 0.010). Regarding 5hmdC levels in the renal cortex and medulla, Spearman's rank correlation test revealed a negative correlation between age and 5hmdC levels (r = - 0.46, p = 0.018 and r = - 0.45, p = 0.042, respectively).
The present results revealed a reduction of 5hmdC levels in the non-tumoral urinary tract mucosa of patients with upper urinary tract urothelial carcinoma. Therefore, the urothelial cell epithelia of patients with upper urinary tract cancer, even in non-cancerous areas, may be predisposed to urothelial cancer.
DNA加合物是由于接触特定致癌物而导致的DNA共价修饰,会引起DNA碱基错配,最终导致DNA突变。启动子区域的DNA甲基化是另一种DNA碱基修饰类型,它会改变DNA转录过程,并且由于肿瘤抑制基因的下调而与人类致癌作用有关。在人类泌尿系统中证明DNA加合物或化学修饰碱基的存在存在困难。除了在特定地理区域(巴尔干地区)导致尿路上皮癌和地方性肾病的马兜铃酸-DNA加合物外,目前关于肾细胞癌和上尿路尿路上皮癌(包括肾盂癌和输尿管癌)的DNA加合物谱的信息有限。
为了阐明DNA加合物在上皮系统致癌作用中的意义,我们使用液相色谱-串联质谱法研究了肾细胞癌、上尿路尿路上皮癌和其他疾病患者的非肿瘤性肾实质和非肿瘤性肾盂中的53种DNA加合物。对组织类型、恶性状态和临床特征(包括生活方式因素)进行了比较分析。
在肾实质和肾盂中检测到了5-甲基-2'-脱氧胞苷、5-羟甲基-2'-脱氧胞苷(5hmdC)、5-甲酰基-2'-脱氧胞苷、2'-脱氧肌苷、8-氧代-2'-脱氧腺苷和8-氧代-2'-脱氧鸟苷(8-OHdG)。8-OHdG在肾盂中的检出频率高于肾皮质和髓质(分别为p = 0.048和p = 0.038)。尿路上皮癌患者(n = 10)肾盂中的5hmdC水平显著低于无尿路上皮癌患者(n = 15)的尿路上皮(p = 0.010)。关于肾皮质和髓质中的5hmdC水平,Spearman等级相关检验显示年龄与5hmdC水平之间呈负相关(分别为r = -0.46,p = 0.018和r = -0.45,p = 0.042)。
本研究结果显示上尿路尿路上皮癌患者非肿瘤性尿路黏膜中的5hmdC水平降低。因此,上尿路癌患者的尿路上皮细胞上皮,即使在非癌区域,也可能易患尿路上皮癌。